Skip to main content
Egetis Therapeutics logo

Egetis Therapeutics — Investor Relations & Filings

Ticker · EGTX ISIN · SE0003815604 LEI · 549300RZCKGWRUBPMY22 ST Manufacturing
Open in API
Filings indexed 282 across all filing types
Latest filing 2024-09-30 Capital/Financing Update
Country SE Sweden
Listing ST EGTX

About Egetis Therapeutics

https://www.egetis.com/

Egetis Therapeutics is an innovative and integrated pharmaceutical company focused on developing and commercializing treatments for serious and rare diseases with significant unmet medical needs. The company's strategy centers on advancing drug candidates through late-stage clinical development to market approval. Its primary asset, Emcitate (tiratricol), is a first-in-class drug candidate in late-stage development for the treatment of Monocarboxylate Transporter 8 (MCT8) deficiency, a rare congenital disorder of thyroid hormone transport.

Recent filings

Filing Released Lang Actions
Egetis Therapeutics avser att genomföra riktade nyemissioner av aktier om cirka 300 miljoner kronor
Capital/Financing Update Classification · 100% confidence The document is a press release from Egetis Therapeutics announcing the intention to conduct a directed share issue (private placement) to raise approximately 300 million SEK. It details the purpose of the capital raise, the involvement of institutional investors, the use of proceeds, and the legal/regulatory disclaimers associated with such a financial transaction. This falls under the category of capital raising and financing activities.
2024-09-30 Swedish
Egetis Therapeutics announces the intention to carry out directed share issuances of approximately SEK 300 million
Capital/Financing Update Classification · 100% confidence The document is a press release from Egetis Therapeutics announcing an intention to carry out a directed share issuance (a capital raise) of approximately SEK 300 million. It details the purpose of the funds, the accelerated bookbuilding procedure, the involvement of institutional investors, and the legal/regulatory disclaimers associated with such a transaction. This falls squarely under the definition of a capital/financing update.
2024-09-30 English
Interim / Quarterly Report 2024
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive financial report for the period ending June 30, 2024 (Q2/Half-year). It includes a 'Finansiell översikt' (Financial Overview) table with comparative data for 2024 and 2023, a 'VD har ordet' (CEO statement), detailed updates on clinical trials (ReTRIACt, Triac Trial II), R&D pipeline information, and a discussion of the company's financial position (cash, financing). Since it contains substantive financial data and analysis for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. H1 2024
2024-08-22 Swedish
Interim / Quarterly Report 2024
Interim / Quarterly Report Classification · 100% confidence The document contains a comprehensive financial overview table (including net revenue, result after tax, cash flow, and earnings per share) for the period ending June 30, 2024. It also includes detailed management commentary on business operations, clinical trial updates, and future outlook. Since it provides substantive financial data and analysis for a period shorter than a full fiscal year (Jan-Jun 2024), it is classified as an Interim/Quarterly Report. H1 2024
2024-08-22 English
Egetis rapporterar topline-resultat från fas 2 studien Triac Trial II med Emcitate® (tiratricol) för behandling av MCT8-brist
Earnings Release Classification · 99% confidence The document is a press release dated June 19, 2024, announcing the topline results from a Phase 2 clinical trial (Triac Trial II) for the drug Emcitate®. It details the study outcomes (not meeting primary endpoints but showing positive effects on T3 concentrations and safety), discusses ongoing regulatory submissions (EMA and FDA), and announces a webcast/conference call for investors. This content structure—announcing key clinical/financial news and scheduling an investor event—is characteristic of an Earnings Release (ER) or a general corporate update. Since it focuses on the immediate release of key performance/trial results rather than being a full, comprehensive report (like a 10-K or IR), 'ER' (Earnings Release) is the most appropriate classification, as it serves as the initial announcement of material period/trial results. The document length is substantial (12,685 chars), ruling out RPA/RNS based on the 'MENU VS MEAL' rule for short announcements. FY 2024
2024-06-19 Swedish
Egetis announces topline results of the Phase 2 Triac Trial II with Emcitate® (tiratricol) for MCT8 deficiency
Earnings Release Classification · 100% confidence The document is a press release announcing the topline results of a clinical trial (Triac Trial II) for a drug candidate (Emcitate®). It details the outcomes, discusses regulatory implications with the EMA and FDA, and schedules a conference call for analysts and investors. This content structure—announcing key results and providing context for investors—is characteristic of an Earnings Release (ER) or a general corporate update. Since it is a specific announcement of financial/trial results rather than a full quarterly/annual report (10-K or IR), Earnings Release (ER) is the most appropriate classification. It is not a proxy statement (DEF 14A), a management discussion (MDA), or a simple report publication announcement (RPA) because it contains the substantive results, not just a notice that a report is available. FY 2024
2024-06-19 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.